Finanzen von Veru Inc (VERU)VERUVeru Inc

Veru Inc. (VERU) generates its revenue primarily from FC2, which accounts for 100.0% of total sales, equivalent to $6.66M. Understanding this concentration is critical for investors evaluating how VERU navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Veru Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.54%, provide a clear picture of how effectively VERU converts its operational activities into shareholder value.

In the context of the broader market, VERU competes directly with industry leaders such as SCYX and TVGN. With a market capitalization of $36.15M, it holds a leading position in the sector. When comparing efficiency, VERU's gross margin of N/A stands against SCYX's N/A and TVGN's N/A. Such benchmarking helps identify whether Veru Inc. is trading at a premium or discount relative to its financial performance.

Veru reported a net loss of $7.0 million for Q3 2026, but this is an improvement from a $7.3 million loss in the same period last year. The company has shown effective cost management, and its cash reserves have increased from $15.8 million to $23.9 million, providing a buffer for future operations.